来源：Gangtise投研

　　锦欣生殖（01951.HK）2024年度业绩发布会：2024年，锦欣生殖的收入达到28.12亿元，同比增加0.81%，但股东应占利润为2.83亿元，同比减少17.88%。国内业务恢复至疫情前水平，美国HRC医疗中心收入创新高，东南亚市场进入区域增长通道。公司取卵周期总数较2023年下降约6.3%，但分娩数量同比增长约5.5%，妇产科服务需求增加。海外业务取卵周期数同比增长约18.2%。锦欣生殖预计2025年将是一个变革期，市场波动较大，因此暂时不会给出业绩指引。尽管2024年业绩受消费因素影响承压，但未来值得期待，如深圳新大楼启用、美国医生产能逐步释放，业绩有望在近年内达到10亿美金以上。公司对现金流增长有信心，预计2025年收入将持续增长，分别为9%和23%。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：王若云

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.